---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-24-000033"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:19:00.540521+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Charles River Q3 revenue $1.01B (-1.6% YoY); non-GAAP EPS $2.59 beats prior outlook; narrows FY guidance

## Summary
- Revenue $1.01B, down 1.6% YoY (organic -2.7%); GAAP EPS $1.33, non-GAAP EPS $2.59.
- DSA segment organic revenue fell 7.4%; Manufacturing organic revenue grew 11.8%.
- Board approved $1B stock repurchase; $100.7M spent in Q3, $899.3M remaining.
- FY 2024 guidance narrowed: reported revenue (3%)-(2%); non-GAAP EPS raised to $10.10-$10.30.
- CEO cites stable demand indicators and biotech funding improvement; restructuring actions continue.

## SEC filing metadata
- accession: 0001100682-24-000033
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068224000033/0001100682-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068224000033/crl-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-24-000033
- JSON: https://secwatch.observer/filing/0001100682-24-000033.json
- Plain text: https://secwatch.observer/filing/0001100682-24-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.